title: Beneficial effect of graft perfusion with anti-T cell receptor monoclonal antibodies on survival of small bowel allografts in rat recipients treated with brequinar alone or in combination with cyclosporine and sirolimus.
abstract: In the present experiments, a multimodality regimen was developed that included an anti-T cell receptor R73 monoclonal antibody and the pharmacologic agents brequinar (BQR), cyclosporine (CsA), and sirolimus (rapamycin; RAPA) to prolong the survival of small bowel (SB) allografts. BQR was the most potent single drug: the 4.0 or 8.0 mg/kg/day BQR doses delivered every second day (q.o.d.) per gavage for 28 days prolonged the survival of Brown Norway (BN; RT1n) SB allografts in Lewis (LEW; RT1l) recipients from a mean survival time of 10.6 +/- 1.9 days in untreated controls to 29.2 +/- 5.8 days, respectively (both P < 0.001). When treatment was extended to 56 days, 8.0 mg/kg/q.o.d BQR produced a mean survival time of 83.8 +/0 33.8 days (P < 0.001), with 2/5 hosts surviving more than 100 days. In a host-versus-graft model, BQR (8.0 mg/kg/q.o.d) delivered for 28 days with CsA (2.0 mg/kg/day) and RAPA (0.04 mg/kg/day) delivered intravenously for 14 days prolonged the survival of BN SB grafts in LEW recipients to 54.4 +/- 21.0 days (P < 0.001). Extending triple-drug therapy to 42 days induced the prolongation of SB allograft survival to greater than 100 days in 5/7 recipients. Although pretransplant perfusion of the grafts with R73 mAb was ineffective alone, the combination of graft perfusion and a 28-day course of BQR (8.0 mg/kg/q.o.d) in the GVH model indefinitely prolonged LEW graft in F1 recipients. Alternatively, indefinite survival of SB allografts ( > 100 days; P < 0.001) was achieved by the combination of a 14-day course of a triple-drug regimen using each agent at subtherapeutic doses, namely BQR (2.0 mg/kg/q.o.d.), CsA (2.0 mg/kg/day), and RAPA (0.04 mg/kg/day). The state of transplantation tolerance is these hosts was documented by the acceptance of donor-type but not third-party heart allografts.
authors.affiliation: Department of Surgery, University of Texas Medical School at Houston 77030, USA.
authors.forename: M
authors.initials: M
authors.lastname: Wang
authors.forename: X
authors.initials: X
authors.lastname: Qu
authors.forename: S M
authors.initials: SM
authors.lastname: Stepkowski
authors.forename: T C
authors.initials: TC
authors.lastname: Chou
authors.forename: B D
authors.initials: BD
authors.lastname: Kahan
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000961:Antilymphocyte Serum / Q000008:administration & dosage*; D001713:Biphenyl Compounds / Q000008:administration & dosage*; D016572:Cyclosporine / Q000008:administration & dosage*; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology; D006086:Graft vs Host Disease / Q000276:immunology / Q000517:prevention & control; D006087:Graft vs Host Reaction / Q000187:drug effects / Q000276:immunology; D006789:Host vs Graft Reaction / Q000187:drug effects / Q000276:immunology; D007108:Immune Tolerance; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007421:Intestine, Small / Q000637:transplantation*; D008297:Male; D010477:Perfusion; D011090:Polyenes / Q000008:administration & dosage*; D051381:Rats; D011912:Rats, Inbred ACI; D011914:Rats, Inbred BN; D011917:Rats, Inbred Lew; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000276:immunology*; D020123:Sirolimus; D013997:Time Factors; D014184:Transplantation, Homologous; D011798:Quinaldines
chemical_list: D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D001713:Biphenyl Compounds; D016572:Cyclosporine; D007166:Immunosuppressive Agents; D011090:Polyenes; D016693:Receptors, Antigen, T-Cell, alpha-beta; D020123:Sirolimus; C046943:brequinar; D011798:Quinaldines